← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Spring Bank Technologies, Inc.
Milford, MA
$6,780,629
Total funding
3
Grants
Funding over time
peak $901.5K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$6,780,629 · 3
By mechanism
R01$3,801,133 · 1
U01$2,379,496 · 1
R43$600,000 · 1
Investigators at Spring Bank Technologies, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent$901,490
R01 · FY2015 · AI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent$856,160
R01 · FY2014 · AI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent$765,000
R01 · FY2011 · AI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent$687,555
R01 · FY2013 · AI
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT$610,629
U01 · FY2007 · AI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent$590,928
R01 · FY2012 · AI
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT$527,243
U01 · FY2005 · AI
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT$500,129
U01 · FY2006 · AI
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT$476,545
U01 · FY2004 · AI
DINUCLEOTIDE ISOMER AS A NOVEL ANTIVIRAL$300,000
R43 · FY2010 · AI
DINUCLEOTIDE ISOMER AS A NOVEL ANTIVIRAL$300,000
R43 · FY2009 · AI
THE DINUCLEOTIDE SB-9000 A NOVEL ANTI-HBV AGENT$264,950
U01 · FY2003 · AI